文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA与11C-胆碱PET/CT对比CT在前列腺癌术后复发中的意向性治疗分析

Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery.
PubMed 文献 · J Nucl Med · 2019-03-08

结果显示PSMA PET与CT分期一致性仅36%,PSMA PET可避免错误治疗并具成本效益,且为既往放疗患者提供新的治愈机会。

要点

  • 68Ga-PSMA PET与诊断CT的TNM分期一致性仅36%,提示CT分期不足。
  • PSMA PET引导下避免1例错误治疗需成像2例(CT)或4例(11C-胆碱PET)。
  • PSMA PET分期使半数既往放疗患者获得新治愈选项而非仅姑息治疗。

核心结论

  • 68Ga-PSMA PET/CT在避免错误治疗方面对所有患者具成本效益。
  • 68Ga-PSMA PET/CT为既往放疗患者提供了新的治愈机会,而这类患者通常仅接受姑息治疗。
  • 因此,68Ga-PSMA PET/CT分期应成为术后伴或不伴放疗后生化复发的标准。

研究设计与样本

  • 前瞻性登记数据库(064/2013BO1)回顾性检索,纳入满足3项标准的患者。
  • 纳入标准:根治性前列腺切除术后生化复发(pT2-pT4 pN0-pN1 cM0,允许术后放疗);24小时内完成11C-胆碱PET/CT、68Ga-PSMA PET/CT和诊断CT;临床数据可用。

主要发现

  • 两种PET检查在72%患者中结果一致。
  • 68Ga-PSMA PET与诊断CT的TNM分期一致性仅36%。
  • 错误分期会导致「错误」治疗并因此增加额外成本。
  • 若额外成本不超过€3,844($4,312)(对比CT),68Ga-PSMA PET具成本效益。
  • 避免1例错误治疗的需成像人数(NNI)为2(CT)和4(11C-胆碱PET)。

关键数值与推荐

  • 中位前列腺特异性抗原水平1.9 ng/mL。
  • 两种PET检查一致率72%。
  • 68Ga-PSMA PET与诊断CT的TNM分期一致率36%。
  • 68Ga-PSMA PET成本效益阈值:额外成本不超过€3,844($4,312)(对比CT)。
  • 避免1例错误治疗的需成像人数:CT为2,11C-胆碱PET为4。

临床怎么用

  • 对于前列腺癌根治术后生化复发患者,应考虑行68Ga-PSMA PET/CT分期以优化治疗决策。
  • 68Ga-PSMA PET/CT有助于避免基于CT错误分期的错误治疗,并可能具有成本效益。
  • 对于既往接受过放疗的患者,68Ga-PSMA PET/CT分期可识别新的治愈机会,避免仅予姑息治疗。

局限性

  • 回顾性研究设计。
  • 单中心登记数据库数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biochemical recurrence (BCR) after prostate cancer surgery is common, even after additional salvage radiotherapy. BCR might be explained by target miss. Improved diagnostic accuracy provided by PET could potentially circumvent this therapeutic gap. Therefore, we evaluated consecutive 68Ga-prostate-specific membrane antigen (PSMA) PET/CT, 11C-choline PET/CT, and standard CT imaging in the same patient with regard to TNM-stage migration and accordingly adapted curative radiotherapy options including ablative treatment of oligometastases (n ≤ 5). The cost efficacy of PET- versus CT-based treatment was also calculated. Methods: The prospective register database (064/2013BO1) was retrospectively searched for patients fulfilling the following 3 inclusion criteria: BCR after radical prostatectomy (pT2-pT4 pN0-pN1 cM0, postoperative radiotherapy allowed); 11C-choline PET/CT, 68Ga-PSMA PET/CT, and diagnostic CT performed within 24 h; and available clinical data. Ten treatment routines were defined according to current practice. Furthermore, intention-to-treat and treatment-related costs depending on the shift of TNM stage after imaging were analyzed. Eighty-three patients were eligible (median prostate-specific antigen level, 1.9 ng/mL). Results: Both PET examinations led to concordant results in 72% of patients, whereas the concordance of TNM staging between 68Ga-PSMA PET and diagnostic CT was only 36%. Incorrect staging would lead to "wrong" treatment and therefore to additional costs. A 68Ga-PSMA PET study would be cost-effective if additional costs do not exceed €3,844 ($4,312) (vs. CT). The number needed to image was 2 (for CT) and 4 (for 11C-choline PET) to avoid 1 incorrect treatment. In addition, 68Ga-PSMA PET staging enabled new curative options in half the patients with previous radiotherapy who otherwise receive palliative androgen deprivation therapy. Conclusion:68Ga-PSMA PET/CT is cost-effective in all patients with regard to avoidance of incorrect treatment. It enabled new curative options for patients with previous radiotherapy who are usually treated palliatively. Therefore, 68Ga-PSMA PET/CT staging should become standard for BCR after surgery with or without radiotherapy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schwenck J, Olthof SC, Pfannenberg C, et al. Intention-to-Treat Analysis of 68Ga-PSMA and 11C-Choline PET/CT Versus CT for Prostate Cancer Recurrence After Surgery. J Nucl Med. 2019. PMID: 30850491. doi:10.2967/jnumed.118.224543

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。